Florian J. Groelly

Florian J. Groelly

Auto-generated profile, based on publicly available information

Florian J. Groelly

Genome Stability and Tumourigenesis Group, Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
FGFlorian J. Groelly
Florian J. Groelly
MFMatthew Fawkes
Matthew Fawkes
RDRebecca A. Dagg
Rebecca A. Dagg
ABAndrew N. Blackford
Andrew N. Blackford
MTMadalena Tarsounas
Madalena Tarsounas

1 October 2020 in Molecular Cell
Verified
Journal Article
Closed access
TRTimo Reisländer
Timo Reisländer
FGFlorian J. Groelly
Florian J. Groelly
MTMadalena Tarsounas
Madalena Tarsounas

17 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TRTimo Reisländer
Timo Reisländer
ELEmilia Puig Lombardi
Emilia Puig Lombardi
FGFlorian J. Groelly
Florian J. Groelly
AMAna Miar
Ana Miar
MPManuela Porru
Manuela Porru
MTMadalena Tarsounas
Madalena Tarsounas
Heterozygous germline mutations in BRCA2 predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where BRCA2 deletion causes cell cycle arrest or cell death, tumors carrying BRCA2 inactivation continue to proliferate. Here we set out to investigate adaptation to loss of BRCA2 focusing on genome-wide transcriptome alterations. Human cells in which BRCA2 expression is inhibited for 4 or 28 days are subjected to RNA-seq analyses revealing a biphasic response to BRCA2 abrogation. The early, acute response consists of downregulation of genes involved in cell cycle progression, DNA replication and repair and is associated with cell cycle arrest in G1. Surprisingly, the late, chronic response consists predominantly of upregulation of interferon-stimulated genes (ISGs). Activation of the cGAS-STING-STAT pathway detected in these cells further substantiates the concept that BRCA2 abrogation triggers cell-intrinsic immune signaling. Importantly, we find that treatment with PARP inhibitors stimulates the interferon response in cells and tumors lacking BRCA2.

2 February 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
FGFlorian J Groelly
Florian J Groelly
MPManuela Porru
Manuela Porru
JZJutta Zimmer
Jutta Zimmer
HBHugo Benainous
Hugo Benainous
YVYanti De Visser
Yanti De Visser
MTMadalena Tarsounas
Madalena Tarsounas
The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication‐associated DNA damage and genomic instability, a signature of BRCA1/2 ‐mutated tumours. Targeted therapies against BRCA1/2 ‐mutated tumours exploit this vulnerability by introducing additional DNA lesions. Because homologous recombination (HR) repair is abrogated in the absence of BRCA1 or BRCA2, these lesions are specifically lethal to tumour cells, but not to the healthy tissue. Ligands that bind and stabilise G‐quadruplexes (G4s) have recently emerged as a class of compounds that selectively eliminate the cells and tumours lacking BRCA1 or BRCA2. Pyridostatin is a small molecule that binds G4s and is specifically toxic to BRCA1/2‐deficient cells in vitro . However, its in vivo potential has not yet been evaluated. Here, we demonstrate that pyridostatin exhibits a high specific activity against BRCA1/2‐deficient tumours, including patient‐derived xenograft tumours that have acquired PARP inhibitor (PARPi) resistance. Mechanistically, we demonstrate that pyridostatin disrupts replication leading to DNA double‐stranded breaks (DSBs) that can be repaired in the absence of BRCA1/2 by canonical non‐homologous end joining (C‐NHEJ). Consistent with this, chemical inhibitors of DNA‐PKcs, a core component of C‐NHEJ kinase activity, act synergistically with pyridostatin in eliminating BRCA1/2‐deficient cells and tumours. Furthermore, we demonstrate that pyridostatin triggers cGAS/STING‐dependent innate immune responses when BRCA1 or BRCA2 is abrogated. Paclitaxel, a drug routinely used in cancer chemotherapy, potentiates the in vivo toxicity of pyridostatin. Overall, our results demonstrate that pyridostatin is a compound suitable for further therapeutic development, alone or in combination with paclitaxel and DNA‐PKcs inhibitors, for the benefit of cancer patients carrying BRCA1/2 mutations.

13 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RDRebecca A. Dagg
Rebecca A. Dagg
GZGijs Zonderland
Gijs Zonderland
ELEmilia Puig Lombardi
Emilia Puig Lombardi
GRGiacomo G. Rossetti
Giacomo G. Rossetti
FGFlorian J. Groelly
Florian J. Groelly
MTMadalena Tarsounas
Madalena Tarsounas
BRCA1orBRCA2germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification andBRCA1/2mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression ofCDKN1Agene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage.